Price
Financials
Consolidated, Rs crore| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.55 | 2.43 | 2.30 | 3.79 | 4.60 | 1.98 | 1.95 | 1.59 | 1.11 | 0.87 | 0.66 | 1.12 |
| Expenses | 2.31 | 1.92 | 1.97 | 1.59 | 1.55 | 1.76 | 1.74 | 1.12 | 1.12 | 0.74 | 1.07 | 0.87 |
| Operating Profit | -0.76 | 0.51 | 0.33 | 2.20 | 3.05 | 0.22 | 0.21 | 0.47 | -0.01 | 0.13 | -0.41 | 0.25 |
| OPM % | -49.03% | 20.99% | 14.35% | 58.05% | 66.30% | 11.11% | 10.77% | 29.56% | -0.90% | 14.94% | -62.12% | 22.32% |
| Other Income | 0.18 | 0.14 | 0.15 | 0.19 | 0.18 | 0.19 | 0.17 | 0.16 | -0.24 | 0.15 | 0.09 | 0.09 |
| Interest | 0.11 | 0.12 | 0.11 | 0.14 | 0.10 | 0.14 | 0.12 | 0.12 | 0.13 | 0.09 | 0.12 | 0.15 |
| Depreciation | 0.12 | 0.13 | 0.13 | 0.16 | 0.11 | 0.12 | 0.12 | 0.12 | 0.27 | 0.11 | 0.11 | 0.11 |
| Profit before tax | -0.81 | 0.40 | 0.24 | 2.09 | 3.02 | 0.15 | 0.14 | 0.39 | -0.65 | 0.08 | -0.55 | 0.08 |
| Tax % | 17.28% | 35.00% | 16.67% | 25.36% | 29.47% | 40.00% | 14.29% | 10.26% | -7.69% | 37.50% | -7.27% | -37.50% |
| Net Profit | -0.95 | 0.26 | 0.20 | 1.55 | 2.13 | 0.09 | 0.12 | 0.35 | -0.60 | 0.05 | -0.51 | 0.10 |
| EPS in Rs | -0.92 | 0.25 | 0.19 | 1.50 | 2.06 | 0.09 | 0.12 | 0.34 | -0.58 | 0.05 | -0.49 | 0.10 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| Sales | 15.45 | 11.41 | 12.78 | 5.94 | 3.76 |
| Expenses | 9.39 | 9.56 | 6.63 | 4.98 | 3.80 |
| Operating Profit | 6.06 | 1.85 | 6.15 | 0.96 | -0.04 |
| OPM % | 39.22% | 16.21% | 48.12% | 16.16% | -1.06% |
| Other Income | 0.51 | 0.69 | 0.67 | 0.26 | 0.09 |
| Interest | 0.39 | 0.45 | 0.54 | 0.55 | 0.49 |
| Depreciation | 0.33 | 0.50 | 0.53 | 0.63 | 0.60 |
| Profit before tax | 5.85 | 1.59 | 5.75 | 0.04 | -1.04 |
| Tax % | 25.30% | 33.33% | 27.65% | 200.00% | |
| Net Profit | 4.37 | 1.06 | 4.15 | -0.04 | -0.96 |
| EPS in Rs | 4.23 | 1.02 | 4.01 | -0.04 | -0.92 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | -27% | -63% | ||
| Compounded Profit Growth | % | % | % | -136% | ||
| Stock Price CAGR | % | -37% | -42% | -71% | ||
| Return on Equity | % | % | 10% | 0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 |
| Reserves | 3.69 | 4.78 | 8.93 | 8.89 | 8.43 |
| Borrowings | 2.03 | 4.57 | 4.88 | 5.84 | 5.73 |
| Other Liabilities | 7.00 | 8.56 | 8.48 | 10.86 | 9.65 |
| Total Liabilities | 23.06 | 28.25 | 32.63 | 35.93 | 34.15 |
| Fixed Assets | 3.50 | 4.62 | 5.07 | 4.45 | 4.22 |
| CWIP | 0.12 | 0.14 | 0.14 | 0.14 | 0.14 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 19.44 | 23.49 | 27.42 | 31.34 | 29.79 |
| Total Assets | 23.06 | 28.25 | 32.63 | 35.93 | 34.15 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Cash from Operating Activity | 5.79 | 2.22 | 0.70 | 0.27 |
| Cash from Investing Activity | -4.12 | -0.94 | -0.32 | 0.25 |
| Cash from Financing Activity | 0.67 | -0.37 | -0.16 | 0.45 |
| Net Cash Flow | 2.34 | 0.91 | 0.22 | 0.97 |
| Free Cash Flow | 4.83 | 0.59 | -0.28 | 0.26 |
| CFO/OP | 107% | 121% | 12% | 31% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 42.05 | 103.97 | 137.37 | 374.22 |
| Inventory Days | ||||
| Days Payable | ||||
| Cash Conversion Cycle | 42.05 | 103.97 | 137.37 | 374.22 |
| Working Capital Days | -31.66 | -161.55 | -81.40 | -75.58 |
| ROCE % | 11.41% | 28.70% | 2.40% |
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 53.10% | 53.10% | 51.73% | 48.47% | 32.82% | 31.99% | 32.09% | 32.09% | 32.09% | 32.09% | 32.09% | 30.17% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 46.90% | 46.90% | 48.26% | 51.53% | 67.18% | 68.01% | 67.91% | 67.90% | 67.89% | 67.91% | 67.89% | 69.82% |
| No. of Shareholders | 1,336 | 2,098 | 2,092 | 2,426 | 3,349 | 3,863 | 4,298 | 4,382 | 4,363 | 4,285 | 4,217 | 4,243 |
Fundamentals
Market Cap₹ 4.66 Cr.
Current Price₹ 4.51
Book Value₹ 18.2
ROCE2.40 %
ROE-0.21 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-63%
Compounded Profit Growth (TTM)-136%
Consolidated figures.
Ownership
Promoter holding30.17% (-1.92 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | 542918 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -0.9% | -2.8% | +1.9 pts |
| 1 month | -5.3% | -6.8% | +1.5 pts |
| 3 months | -7.8% | -7.6% | -0.2 pts |
| 3 years | -80.3% | +14.2% | -94.5 pts |
| 5 years | -90.0% | +27.9% | -117.9 pts |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Dec 2025Sales ₹1 Cr -29.6% vs Dec 2024.
Net profit ₹0 Cr -71.4%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Dr Lal Pathlabs Ltd | 32,737 | 58.2 | 28.0 % |
| Vijaya Diagnostic Centre Ltd | 15,192 | 81.0 | 20.5 % |
| Metropolis Healthcare Ltd | 11,665 | 56.0 | 17.8 % |
| Thyrocare Technologies Ltd | 8,708 | 48.2 | 35.4 % |
| Nephrocare Health Services Ltd | 6,671 | 78.4 | 15.3 % |
| Suraksha Diagnostic Ltd | 1,847 | 51.6 | 17.3 % |
| Krsnaa Diagnostics Ltd | 1,791 | 18.1 | 12.7 % |
| 3B Blackbio DX Ltd | 1,396 | 25.1 | 25.5 % |
| One Global Service Provider Ltd | 1,046 | 14.1 | 87.0 % |
| Health X Platform Ltd | 923 | 0.03 % | |
| Gaudium IVF and Women Health Ltd | 830 | 35.9 | 29.3 % |
| Chandan Healthcare Ltd | 581 | 22.1 | 23.3 % |
| Pramodini Medicare Ltd | 259 | 14.9 | 41.8 % |
| Aspira Pathlab & Diagnostics Ltd | 148 | 2.84 % | |
| Choksi Laboratories Ltd | 132 | 69.2 | 9.44 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Gian Lifecare Ltd?
Gian Lifecare Ltd (542918) has a market capitalisation of Rs 4.66 Cr. at the 2026-10-01 close.
What were Gian Lifecare Ltd's latest quarterly results?
In the Dec 2025 quarter, Gian Lifecare Ltd sales was Rs 1 Cr (-29.6% vs Dec 2024) and net profit was Rs 0 Cr.